Akebia Therapeutics Inc. (NASDAQ:AKBA) remained unchanged to close Friday at $1.25 after subtracting $0.0 on the day. The 5-day average trading volume is 1,046,960 shares of the company’s common stock. It has gained $1.3696 in the past week and touched a new high 2 times within the past 5 days. An average of 2,356,400 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,921,988.
AKBA’s 1-month performance is 1.63% or $0.0800 on its low of $1.1800 reached on 07/19/23. The company’s shares have touched a 52-week low of $0.24 and high of $1.84, with the stock’s rally to the 52-week high happening on 08/01/23. YTD, AKBA has achieved 116.64% or $0.6730 and has reached a new high 14 times. However, the current price is down -32.07% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AKBA stock investors last saw insider trading activity on May 25.Dahan Michel (SVP, Chief Operating Officer) most recently sold 95,478 shares at $1.22 per share on May 25. This transaction cost the insider $116,760. SVP, Chief Legal Officer, Hadas Nicole R., sold 63,186 shares at a price of $1.22 on May 25. Then, on May 16, SVP, Chief Medical Officer Burke Steven Keith sold 63,567 shares at a price of $1.07 per share. This transaction amounted to $67,890.
Valuation Metrics
AKBA stock has a beta of 0.87. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.86.
Akebia Therapeutics Inc.’s quick ratio for the period ended March 30 was 1.20, with the current ratio over the same period at 1.50. In terms of profitability, the gross margin trailing 12 months is 85.30%. The trailing 12-month EBITDA margin is -9.54% while for the period ending March 30, Akebia Therapeutics Inc.’s operating margin was -17.10%. The firm’s gross profit as reported stood at $207.81 million against revenue of $292.6 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -138.06% to -$26.22 million, while revenue of -$7.55 million was 71.21% off the previous quarter. Analysts expected AKBA to announce -$0.15 per share in earnings in its latest quarter, but it posted -$0.14, representing a 6.70% surprise. EBITDA for the quarter stood at more than -$15.53 million. AKBA stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 291.21 million, with total debt at $82.87 million. Shareholders hold equity totaling $185.93 million.
Let’s look briefly at Akebia Therapeutics Inc. (AKBA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 38.20% to suggest the stock is trending Neutral, with historical volatility in this time period at 83.06%.
The stock’s 5-day moving average is $1.2780, reflecting a -0.79% or -$0.0100 change from its current price. AKBA is currently trading -0.79% above its 20-day SMA, +90.46% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -2.34% and SMA200 by+391.16%.
Stochastic %K and %D was 7.79% and 9.27% and the average true range (ATR) pointed at 0.1310. The RSI (14) points at 44.28%, while the 14-day stochastic is at 9.23% with the period’s ATR at 0.1339. The stock’s 9-day MACD Oscillator is pointing at -0.1011 and -0.2045 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Akebia Therapeutics Inc. (NASDAQ: AKBA), Piper Sandler upgraded it to an Overweight rating. They previously had a Neutral rating on the stock. Analysts offering their rating for AKBA stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate AKBA as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is AKBA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.00 and a high of $4.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Akebia Therapeutics Inc. (AKBA) stock is $3.00.
